查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2038549

全球骨質疏鬆症治療市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

Global Osteoporosis Treatment Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 151 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球骨質疏鬆症治療市場預計將從2025年的215.5億美元成長至2034年的335.4億美元，2026年至2034年的複合年成長率（CAGR）為5.04%。人口老化和人們對骨骼健康的日益關注推動了該市場的擴張。骨質疏鬆症的特徵是骨骼密度下降，會增加骨折和併發症的風險。隨著醫療保健系統將重點轉向預防醫學和長期疾病管理，對有效治療方法的需求也不斷成長。

推動骨質疏鬆症市場成長的主要因素包括骨質疏鬆症盛行率的上升、藥物治療的進步以及公眾健康意識的提高。雙磷酸鹽、荷爾蒙療法和生物製劑等治療方法被廣泛用於治療疾病。診斷工具和篩檢項目的擴展也促進了市場成長。此外，政府為促進骨骼健康和預防醫學所採取的措施也推動了治療方法的廣泛應用。

展望未來，包括個人化醫療和先進生物製藥在內的治療方法將持續創新。更有效、更安全的治療方法的發展將改善患者的治療效果。由於醫療保健服務的普及，新興市場預計將顯著成長。隨著人們對骨質疏鬆症的認知不斷提高以及診斷技術的進步，骨質疏鬆症治療市場預計將持續擴張。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節提供清晰的市場概覽，包括關鍵定義、分類和當前產業格局。

市場動態：對影響市場成長的主要促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分依據產品類型、應用、最終使用者和地區，將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭動態以及主要參與者所採取的策略。

市場預測：本預測是基於特定預測期內的市場規模和成長模式數據。本節結合歷史趨勢、當前市場狀況和定量分析，揭示未來預期趨勢。

區域分析：本部分全面回顧了主要地理區域的市場表現，確定了高成長領域和區域趨勢，從而更深入地了解區域市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的客製化服務，可根據您的具體需求自訂報告。這包括額外的細分、特定國家/地區的分析、競爭對手分析、客製化資料點或專注於特定細分市場的洞察，以更好地支持您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章 全球骨質疏鬆症治療市場：依藥物類別分類

  • 市場分析、洞察與預測
  • 雙磷酸鹽
  • 荷爾蒙補充療法
  • 選擇性雌激素受體調節（SERMs）
  • RANK配體（RANKL）抑制劑
  • 其他

第5章 全球骨質疏鬆症治療市場：依給藥途徑分類

  • 市場分析、洞察與預測
  • 口服
  • 腸外

第6章 全球骨質疏鬆症治療市場：依通路分類

  • 市場分析、洞察與預測
  • 醫院和藥房
  • 零售藥局和商店
  • 網路藥房

第7章 全球骨質疏鬆症治療市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第8章 競爭情勢

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第9章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • AbbVie Inc
    • Eli Lilly And Company
    • Amgen Inc
    • F. Hoffmann-La Roche Ltd
    • Novartis AG
    • Sanofi
    • Pfizer Inc
    • Merck & Co. Inc
    • GlaxoSmithKline Plc
簡介目錄
Product Code: VMR11212018

The global osteoporosis treatment market size is expected to reach USD 33.54 Billion in 2034 from USD 21.55 Billion in 2025, growing at a CAGR of 5.04 during 2026-2034.This market is growing as the aging population increases and awareness about bone health improves. Osteoporosis, a condition characterized by reduced bone density, leads to a higher risk of fractures and complications. The demand for effective treatment options is rising as healthcare systems focus on preventive care and long-term disease management.

Key drivers include the increasing prevalence of osteoporosis, advancements in pharmaceutical therapies, and rising healthcare awareness. Treatments such as bisphosphonates, hormone therapy, and biologics are widely used to manage the condition. The expansion of diagnostic tools and screening programs is also supporting market growth. Additionally, government initiatives promoting bone health and preventive care are contributing to increased adoption.

Future prospects indicate continued innovation in treatment options, including personalized medicine and advanced biologics. The development of more effective and safer therapies will improve patient outcomes. Emerging markets are expected to witness significant growth due to increasing healthcare access. As awareness and diagnosis improve, the osteoporosis treatment market is set for sustained expansion.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Drug Class

  • Bisphosphonate
  • Hormone Replacement Therapy
  • Selective Estrogen Receptor Modulator (SERMs)
  • RANK ligand (RANKL) Inhibitor
  • Others

By Route of Administration

  • Oral
  • Parenteral

By Distribution Channel

  • Hospitals Pharmacies
  • Retail Pharmacies & Stores
  • Online Pharmacies

COMPANIES PROFILED

  • AbbVie Inc., Eli Lilly and Company, Amgen Inc., F. Hoffmann-La Roche Ltd, Novartis AG, Sanofi, Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL OSTEOPOROSIS TREATMENT MARKET: BY DRUG CLASS 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Drug Class
  • 4.2. Bisphosphonate Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Hormone Replacement Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Selective Estrogen Receptor Modulator (SERMs) Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. RANK ligand (RANKL) Inhibitor Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.6. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL OSTEOPOROSIS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Route Of Administration
  • 5.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Parenteral Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL OSTEOPOROSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Distribution Channel
  • 6.2. Hospitals Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Retail Pharmacies & Stores Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL OSTEOPOROSIS TREATMENT MARKET: BY REGION 2022-2034 (USD MN)

  • 7.1. Regional Outlook
  • 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.2.1 By Drug Class
    • 7.2.2 By Route Of Administration
    • 7.2.3 By Distribution Channel
    • 7.2.4 United States
    • 7.2.5 Canada
    • 7.2.6 Mexico
  • 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.3.1 By Drug Class
    • 7.3.2 By Route Of Administration
    • 7.3.3 By Distribution Channel
    • 7.3.4 United Kingdom
    • 7.3.5 France
    • 7.3.6 Germany
    • 7.3.7 Italy
    • 7.3.8 Russia
    • 7.3.9 Rest Of Europe
  • 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.4.1 By Drug Class
    • 7.4.2 By Route Of Administration
    • 7.4.3 By Distribution Channel
    • 7.4.4 India
    • 7.4.5 Japan
    • 7.4.6 South Korea
    • 7.4.7 Australia
    • 7.4.8 South East Asia
    • 7.4.9 Rest Of Asia Pacific
  • 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.5.1 By Drug Class
    • 7.5.2 By Route Of Administration
    • 7.5.3 By Distribution Channel
    • 7.5.4 Brazil
    • 7.5.5 Argentina
    • 7.5.6 Peru
    • 7.5.7 Chile
    • 7.5.8 Rest of Latin America
  • 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 7.6.1 By Drug Class
    • 7.6.2 By Route Of Administration
    • 7.6.3 By Distribution Channel
    • 7.6.4 Saudi Arabia
    • 7.6.5 UAE
    • 7.6.6 Israel
    • 7.6.7 South Africa
    • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

  • 8.1. Recent Developments
  • 8.2. Company Categorization
  • 8.3. Supply Chain & Channel Partners (based on availability)
  • 8.4. Market Share & Positioning Analysis (based on availability)
  • 8.5. Vendor Landscape (based on availability)
  • 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL OSTEOPOROSIS TREATMENT INDUSTRY

  • 9.1. Top Companies Market Share Analysis
  • 9.2. Company Profiles
    • 9.2.1 AbbVie Inc
    • 9.2.2 Eli Lilly And Company
    • 9.2.3 Amgen Inc
    • 9.2.4 F. Hoffmann-La Roche Ltd
    • 9.2.5 Novartis AG
    • 9.2.6 Sanofi
    • 9.2.7 Pfizer Inc
    • 9.2.8 Merck & Co. Inc
    • 9.2.9 GlaxoSmithKline Plc